Imidex, a medical device company leveraging AI for enhanced lung cancer detection, has recently formed a strategic partnership with Orbit Genomics, a specialist in DNA-sequencing technologies. Together, they aim to significantly reduce lung cancer fatalities by merging their distinctive technological solutions. Imidex is known for its FDA 510(k)-cleared VisiRad XR device, which efficiently detects lung nodules as small as 6mm through chest X-rays, boasting an 83% sensitivity rate. Orbit Genomics contributes with its OrbiSeq-L product, designed to diagnose lung cancer in patients who present with unspecified pulmonary nodules detected through low-dose CT scans, and is gearing up to initiate clinical trials.
The collaboration between Imidex and Orbit Genomics will see the integration of their services to offer a comprehensive lung cancer detection and diagnosis solution. The plan is to utilize Imidex’s VisiRad XR for initial lung nodule detection via chest X-ray, followed by Orbit’s OrbiSeq-L testing for those patients with detected nodules. This process is expected to provide a potentially life-saving diagnostic follow-up, enabling effective and tailored treatment options.
Dede Willis, president, and CEO of Orbit Genomics elaborated on the strategic partnership, emphasizing the synergy between the two technologies. Imidex’s VIsiRad XR serves as an initial filter in the lung cancer identification process by using X-rays, a less invasive method compared to CT scans, to detect potential lung cancer cases. OrbiSeq-L can then be used to perform immediate and highly specific tests on those identified patients, using just a simple blood sample to gain detailed insights into their condition and guide them towards the most appropriate care.
The partnership not only focuses on immediate cancer detection and diagnosis but also contemplates broader applications of the OrbiSeq technology platform. Beyond lung cancer, this technology shows potential utility in diagnosing and managing a variety of other diseases and conditions, including cardiac and neurological disorders.
Imidex itself is no stranger to collaborations aimed at enhancing cancer detection. In July, prior to the partnership with Orbit Genomics, Imidex teamed up with Spesana, a company specializing in personalized medicine technology. Their joint goal is to measure the impact of AI on the detection efficiencies of lung nodules and masses. This project aims to increase lung cancer detection rates, utilize screening to identify patients eligible for clinical trials, and assess the potential application of liquid biopsies subsequent to nodule detection on chest X-rays.
Furthermore, the recent developments at Orbit Genomics also include its successful graduation from the inaugural cohort of the CancerX Accelerator Program, a part of the broader Cancer Moonshot initiative spearheaded by President Joe Biden. First launched during his vice presidency and reignited in 2022 during his presidency, the Cancer Moonshot aims to accelerate advancements in cancer treatments and increase accessibility. The CancerX, under the Department of Health and Human Services, is a public-private cooperative striving to expedite cancer-related innovations in the United States. Orbit Genomics was selected from over a hundred startups to partake in this prestigious program, gaining valuable mentorship and hands-on experience at the Moffitt Cancer Center.
The synergy between Imidex and Orbit Genomics could potentially usher in a new era of early lung cancer detection and management, greatly improving patient outcomes and reducing lung cancer-related fatalities through their innovative combination of AI-driven diagnostics and genetic sequencing technologies.
#Imidex #partners #Orbit #Genomics #detect #earlystage #lung #cancer
